Mesothelioma Drug Pipeline Analysis Report 2025

Mesothelioma is a rare and aggressive cancer caused by asbestos exposure, accounting for merely 0.17% of total estimated cancer cases. It presents as pleural, peritoneal, pericardial, and testicular mesothelioma. There is a high unmet clinical need for better therapies, as current treatment options, such as chemotherapy and radiation, offer limited efficacy. The pipeline for mesothelioma therapeutics is expanding with novel immunotherapies, targeted therapies, and gene-based treatments. The rising focus on personalized medicine and innovative drug development is likely to support pipeline growth in the coming years, offering hope for improved patient outcomes.

Report Coverage

The Mesothelioma Drug Pipeline Insight Report by the publisher gives comprehensive insights into mesothelioma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for mesothelioma. The mesothelioma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The mesothelioma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with mesothelioma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to mesothelioma.

Mesothelioma Drug Pipeline Outlook

Mesothelioma is a rare, aggressive cancer that develops in the mesothelial cells lining the lungs, abdomen, or heart. It is primarily caused by asbestos exposure, which leads to inflammation and genetic mutations over time. Symptoms often appear decades after exposure, making early diagnosis challenging.

Mesothelioma treatment includes surgery, chemotherapy, and radiation therapy. These options aim to control symptoms, reduce tumor size, and prolong survival. Emerging immunotherapies and targeted treatments are showing promise, offering hope for better outcomes in the future.

Mesothelioma Epidemiology

Mesothelioma, a rare cancer accounting for only 0.17% of all cancer cases, witnesses around 3,000 new diagnoses annually in the United States, affecting roughly 1 in 100,000 individuals. In the United Kingdom, it ranks as the 19th most common cause of cancer death, contributing to 1% of all cancer-related fatalities. The ongoing development of mesothelioma therapeutics is crucial in addressing the current medical needs.

Mesothelioma Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of mesothelioma drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• CAR-T Cell Therapies
• Gene Therapies
• RNA-Based Therapies
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Mesothelioma - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase I accounts for a major share of the total mesothelioma clinical trials.

Mesothelioma Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered in the mesothelioma pipeline analysis include small molecules, monoclonal antibodies, CAR-T cell therapies, gene therapies, RNA-based therapies, and others. The mesothelioma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for mesothelioma.

Mesothelioma Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the mesothelioma drug pipeline covers the profiles of key companies involved in clinical trials and their drugs under development. It provides a detailed mesothelioma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in mesothelioma clinical trials:

• Novartis Pharmaceuticals
• Bristol-Myers Squibb
• MedImmune LLC
• PrECOG, LLC
• Oncovir, Inc.
• Verismo Therapeutics
• InSilico Medicine Hong Kong Limited
• BridGene Biosciences Inc.
• AstraZeneca
• Merck Sharp & Dohme LLC
• Hoffmann-La Roche

Mesothelioma Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for mesothelioma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of mesothelioma drug candidates.

Drug: Durvalumab + Chemotherapy

The DREAM3R trial, sponsored by PrECOG, LLC, aims to assess whether adding durvalumab to standard chemotherapy enhances overall survival in advanced pleural mesothelioma patients. This Phase III study will involve about 214 participants and will compare durvalumab plus chemotherapy versus physician-chosen treatment. It is expected to be completed by February 2026.

Drug: Tremelimumab

MedImmune LLC is sponsoring a Phase IIb randomized, double-blind study evaluating Tremelimumab for unresectable pleural or peritoneal malignant mesothelioma. The objective is to assess its efficacy and safety compared to a placebo. The trial involves around 571 participants across multiple countries and is expected to conclude by April 2025.

Drug: IAG933

A Phase I study, sponsored by Novartis Pharmaceuticals, aims to evaluate the safety and tolerability of IAG933 in advanced mesothelioma and other solid tumors. This trial aims to determine the maximum tolerated dose and recommended dosage. The study is expected to conclude by September 2026 and will involve approximately 156 participants across multiple centers.

Reasons To Buy This Report

The Mesothelioma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for mesothelioma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into mesothelioma collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Mesothelioma - Pipeline Insight Report

• Which companies/institutions are leading the mesothelioma drug development?
• What is the efficacy and safety profile of mesothelioma pipeline drugs?
• Which company is leading the mesothelioma pipeline development activities?
• What is the current mesothelioma commercial assessment?
• What are the opportunities and challenges present in the mesothelioma drug pipeline landscape?
• What is the efficacy and safety profile of mesothelioma pipeline drugs?
• Which company is conducting major trials for mesothelioma drugs?
• Which companies/institutions are involved in mesothelioma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in mesothelioma?

This product will be delivered within 3-5 business days.